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Sciences. Dr. McGuire hhis study sought to examine the reliability and prognostic importance of an in-hospital diagnosis of metabolic
syndrome (MetS) in the setting of acute myocardial infarction (AMI).Background Because the factors that comprise MetS are believed to be altered in the setting of AMI, the diagnosis of MetS during
AMI hospitalization and its prognostic signiﬁcance have not been studied.Methods We assessed patients within a multicenter registry for metabolic factors at baseline and 1 month post-AMI and
followed them for mortality and rehospitalizations. The accuracy of an inpatient diagnosis of MetS was calculated
using a 1-month follow-up as the gold standard. Patients were categorized based on MetS diagnosis at baseline and
1 month, and the combined endpoint of death or rehospitalization over 12 months was compared between groups.Results Of the 1,129 patients hospitalized for AMI, diagnostic criteria for MetS were met by 69% during AMI hospitalization
and 63% at 1 month. Inpatient MetS diagnosis had a sensitivity and speciﬁcity for outpatient diagnosis of 87% and
61%, respectively, and was associated with an 11 times increased odds of an outpatient diagnosis (C-index 0.74).
Compared with patients without MetS during hospitalization and follow-up, patients classiﬁed as MetS during AMI
but not follow-up had worse outcomes, whereas those classiﬁed MetS at follow-up had the worst outcomes (rates for
combined endpoint 27% vs. 37% vs. 38%; log-rank p ¼ 0.01).Conclusions In a large cohort of patients with AMI, the diagnosis of MetS is common and can be made with reasonable accuracy
during AMI. MetS is associated with poor outcomes, regardless of whether the diagnosis is conﬁrmed during
subsequent outpatient visit, and identiﬁes a high-risk cohort of patients that may beneﬁt from more aggressive risk
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Figure 1 Flow Chart of Patients in Study Cohort
Patients could opt for 1-month follow-up by telephone or in-home visit, which
allowed for collection of additional clinical and laboratory data. Only patients with
baseline and 1-month assessments sufﬁcient to determine the presence or
absence of metabolic syndrome were included.
Abbreviations
and Acronyms
AMI = acute myocardial
infarction
CAD = coronary artery
disease
MetS = metabolic syndrome
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705However, an earlier diagnosis of MetS may allow for better
risk stratiﬁcation and initiation of aggressive risk factor
modiﬁcation before discharge, when changes have the greatest
likelihood of being implemented by the patient (2,3).
Methods
Study population and protocol. Details of the TRIUMPH
(Translational Research Investigating Underlying Dispar-
ities in Acute Myocardial Infarction Patients’ Health Status)
prospective cohort study have been previously published (4).
Brieﬂy, 4,340 patients from 24 U.S. hospitals were enrolled
into the TRIUMPH registry (2005 to 2008). All patients
had biomarker evidence of myocardial necrosis and addi-
tional clinical evidence supporting the diagnosis of AMI.
Baseline data were obtained through chart abstraction and
detailed interviews. Consenting patients had their waist
circumference measured and fasting blood specimens
collected before discharge. Blood was analyzed at a core
laboratory (Clinical Reference Laboratory, Lenexa, Kansas)
for glucose and lipid levels. Laboratory values determined for
clinical purposes were recorded and used if core data were
unavailable. Patients could opt for 1-month follow-up by
telephone or in-home visit, which allowed for collection of
additional clinical and laboratory data. The ﬁnal blood pres-
sure recorded in the chart was used for baseline assessment.
MetS was determined using Adult Treatment Panel III
criteria (Online Exhibit A) (5). Although antihypertensive
medications are typically included in this deﬁnition, we
excluded beta blockers (all patients) and angiotensin-
converting enzyme inhibitors or angiotensin II receptor
blockers (patients with ventricular dysfunction) because these
may have been used for purposes other than blood pressure
control.Only patients with baseline and 1-month assessments
sufﬁcient to determine the presence or absence of MetS were
included (Fig. 1). Patients were interviewed 6 and 12 months
post-AMI, and charts from patients reporting interim reho-
spitalizations were requested and adjudicated (4). Mortality
was assessed by the Social Security Death Masterﬁle. Each
participating hospital obtained institutional research board
approval, and all patients provided written informed consent.
Statistical analysis. Patients were categorized into 4 groups:
1) noMetS baseline and noMetS 1-month (MetS/MetS);
2) MetS baseline and no MetS 1-month (MetSþ/MetS); 3)
noMetSbaseline andMetS1-month (MetS/MetSþ); and4)
MetS baseline and 1-month (MetSþ/MetSþ). Sensitivity,
speciﬁcity, positive predictive value, and negative predictive
value were calculated for MetS diagnosis at baseline as
a predictor of outpatient MetS and for the 5 individual MetS
components. Logistic regression was used to evaluate the ability
of baselineMetSdiagnosis topredict follow-upMetSdiagnosis.
Kaplan-Meier curves were used to compare time to all-cause
death or rehospitalization from 1 to 12 months post-AMI
across the MetS groups, and Cox proportional hazards were
used to estimate hazard ratios (HRs), adjusted for the GRACE
(Global Registry of Acute Coronary Events) discharge score (6).
Because the outpatient diagnosis ofMetS is the gold standard,wecombined MetS/MetSþ and
MetSþ/MetSþ groups into “true
MetS” for the outcomes analysis
(for 4-group sensitivity analysis, see
Online Fig. 1). Finally, we explored
whether the association between
MetS and prognosis was attribut-
able solely to the presence or
absence of diabetes.
All analyses were conducted using SAS version 9.2 (SAS
Institute, Inc., Cary, North Carolina), and statistical signif-
icance was determined by a 2-sided p value of < 0.05.Results
Patient population. Of the 4,266 patients enrolled in the
TRIUMPH study who survived 1 month after AMI, 1,303
agreed to an in-home assessment with blood draw. Among
those, 1,129 patients (87%) had sufﬁcient metabolic data at
baseline and after 1 month to determine the presence or
absence of MetS (Fig. 1; for generalizability analysis, see
Online Exhibit B). Overall, participants had an average age
of 59.7 years, 34% were women, and the average body mass
index was 29.9 kg/m2. Diabetes was present in 29.4%, and
20.4% had a prior AMI.
Figure 2
Prevalence of the Components of Metabolic
Syndrome During and After AMI Hospitalization
The number of patients who met diagnostic criteria for metabolic syndrome
and each of the individual components during acute myocardial infarction
(AMI) hospitalization and at 1-month follow-up are shown. BP ¼ blood pressure;
HDL-C ¼ high-density lipoprotein cholesterol; TG ¼ triglycerides.
Table 1
Accuracy of Baseline Assessment of MetS and Its
Components for 1-Month Post-AMI Assessment
Sensitivity Speciﬁcity PPV NPV
Metabolic syndrome 87.2% 61.2% 79.3% 73.8%
Abdominal obesity 92.7% 87.8% 91.6% 89.3%
High triglycerides 64.4% 77.0% 66.3% 75.5%
Low HDL-C 82.4% 60.2% 76.1% 69.1%
High blood pressure 93.5% 61.1% 89.7% 72.3%
Impaired fasting
glucose/diabetes
85.7% 57.6% 70.0% 77.7%
HDL-C ¼ high-density lipoprotein cholesterol; NPV ¼ negative predictive value; PPV ¼ positive
predictive value.
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706Sensitivity, speciﬁcity, positive predictive value, and
negative predictive value. Diagnostic criteria for MetS
were met by 69% of patients during AMI hospitalization
and 63% at 1-month follow-up (Fig. 2). The percentage
meeting each criterion of MetS was similar between
assessments (5%) with the exception of impaired fasting
blood glucose (66% at baseline vs. 54% at 1 month). In
terms of individual patients, the MetS classiﬁcation was
changed for 22% from baseline to 1 month. The sensitivity
and speciﬁcity of MetS diagnosis at baseline for the diag-
nosis at 1 month were 87% and 61%, respectively (Table 1).
The most stable individual component was abdominal
obesity, and the 3 laboratory assessments were more unstable
from baseline to 1 month. MetS diagnosis during hospi-
talization was associated with a 10.8 times increased odds
(95% conﬁdence interval [CI]: 8.0 to 14.5) of outpatient
MetS diagnosis (C-index 0.742).
Patient characteristics of different metabolic groups. The
demographics and clinical characteristics of the 4 metabolic
groups, based on the diagnosis of MetS during index
hospitalization and at 1 month post-AMI, are shown in
Table 2. Patients categorized as MetSþ during index
hospitalization were more likely to have diabetes and to have
multivessel disease on angiogram. Patients identiﬁed as
MetSþ during index hospitalization had worse metabolic
values across the spectrum of measured factors comparedwith patients categorized as MetS, including higher body
mass index, higher triglyceride levels, lower high-density
lipoprotein cholesterol (HDL) levels, and higher glucose
and insulin levels (Online Table 1).
Outcomes of different metabolic groups. Patients with no
MetS at baseline and follow-up had the best outcomes over
the year following AMI (mortality 2.0%; rehospitalization
25.6%). Patients classiﬁed as MetSþ during the AMI but
not follow-up had worse outcomes (mortality 2.5%; reho-
spitalization 33.7%). True MetS patients (MetS/MetSþ
and MetSþ/MetSþ; see the Online Appendix for 4-group
analysis) had the worst outcomes (mortality 4.1%; rehospi-
talization 36.2%), with rates of combined endpoints: 27%
versus 37% versus 38%, respectively (log-rank p ¼ 0.01)
(Fig. 3). In analyses adjusted for GRACE score (a measure
of AMI severity), MetSþ/MetS was associated with
a nonsigniﬁcant trend toward increased hazard of death or
rehospitalization (HR: 1.39; 95%CI: 0.96 to 2.01; p¼ 0.082),
and true MetS was associated with a signiﬁcantly increased
hazard (HR: 1.56; 95%CI: 1.19 to 2.06; p¼ 0.002) (reference
MetS/MetS).
To examine whether the association between MetS and
prognosis was driven by a concurrent diagnosis of diabetes,
we additionally adjusted for diabetes and the interaction of
diabetes MetS. The interaction terms were not statistically
signiﬁcant (p > 0.1), indicating that the association of the
MetS group with poor outcomes did not vary according to
diabetes status. Furthermore, among patients without dia-
betes, the association betweenMetS group and poor outcome
remained consistent (Online Fig. 2).
Discussion
In this large, multicenter prospective AMI cohort study, the
diagnosis of MetS was exceedingly common both at the time
of AMI and at 1 month after the acute event. Although
many of the individual components may have been altered
during the AMI, the diagnosis of MetSdas a constellation
of factorsdhas reasonable accuracy at the time of AMI
hospitalization. Furthermore, patients identiﬁed as MetS
during the AMI were at high risk for poor outcomes,
regardless of the MetS diagnosis at the 1-month follow-up.
Therefore, identifying these patients at the time of an
Table 2 Baseline Characteristics of 4 Groups Based on Baseline and 1-Month Diagnoses of MetS
No MetS MetS
p Value
MetS/MetS
(n ¼ 256)
MetSþ/MetS
(n ¼ 162)
MetS/MetSþ
(n ¼ 91)
MetSþ/MetSþ
(n ¼ 620)
Age, yrs 61.6  12.0 58.2  11.4 61.8  13.0 58.9  11.1 0.002
Female 27.0% 29.0% 30.8% 38.7% 0.003
White 74.5% 79.0% 75.8% 71.5% 0.491
Current smoker 40.9% 44.7% 34.1% 35.9% 0.131
Prior myocardial infarction 15.2% 15.4% 19.8% 23.9% 0.010
Prior angioplasty 11.7% 18.5% 20.9% 23.9% <0.001
Prior bypass surgery 8.6% 7.4% 9.9% 15.2% 0.007
Hypertension 51.6% 52.5% 67.0% 76.3% <0.001
Diabetes 5.9% 13.0% 15.4% 45.5% <0.001
ST-segment elevations 54.3% 47.5% 46.2% 44.2% 0.058
Multivessel disease (2 vessels) 42.5% 48.4% 36.7% 54.3% 0.001
LV dysfunction 46.7% 40.7% 34.1% 32.0% <0.001
GRACE score 102.4  28.2 94.8  26.3 104.3  28.5 99.3  27.8 0.019
Values are mean  SD or %.
GRACE ¼ Global Registry of Acute Coronary Events; LV ¼ left ventricular; MetS ¼ metabolic syndrome.
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707AMIdwhen therapeutic and lifestyle changes are most
likely to occur (2,3)dis not only feasible but may also be
optimal from a patient care perspective. Importantly, the
components of MetS are all measures routinely collected as
part of clinical care; therefore, these patients can be easily
“ﬂagged” as MetS (and high risk) to the treating physician.
These patients could then be targeted for more intensive
lifestyle changes, closer follow-up, and reassessment during
the subsequent outpatient physician visit.
Prior studies. MetS is generally considered a constellation
of factors that increases an individual’s risk for developing
diabetes or a primary cardiac event, and its prognostic
importance has been demonstrated most often in this
capacity (7,8). Therefore, it is not surprising that theFigure 3
Survival Free From Death or Rehospitalization Across
Metabolic Groups
MetS/MetS ¼ no metabolic syndrome (MetS) at baseline and after 1 month
(n ¼ 256). MetSþ/MetS ¼ MetS at baseline but not at 1 month (n ¼ 162).
MetSþ/MetSþ and MetS/MetSþ ¼ true MetS patients (i.e., MetS diagnosed as
an outpatient; n ¼ 711).prevalence of MetS among patients with AMI in our study
was much higher than that in the general American adult
population (approximately 25% [9]) or among patients with
stable CAD (approximately 40% to 50% [10]). Importantly,
MetS in our study was associated with adverse prognosis after
an AMI, even after adjustment for the GRACE score.
Although patients with AMI are already considered high risk
for recurrent ischemic events, the diagnosis of MetS
has additional prognostic value even in this high-risk pop-
ulation. Although there is some evidence of an increased risk in
the stable CAD population (1), this was mostly observed in
patients with concomitant diabetes (10). Our study showed
that the diagnosis of MetS made in the setting of AMI also
conferred a poor prognosis, independent of diabetes.
Study limitations. First, many patients declined partici-
pation in the metabolic substudy of the TRIUMPH trial.
However, because the baseline characteristics of nonpartic-
ipants were similar to those of participants, the analytic
population remained fairly representative of a general AMI
population who survives to 1 month after AMI. Second,
because of a low number of events, we were limited in our
ability to adjust for a large number of covariates in our
outcomes models. Nevertheless, we adjusted for the
GRACE score, which integrates many prognostically
important variables and has excellent predictive value for
long-term post-AMI mortality (6). Finally, although we
demonstrated an association of MetS with poor outcomes
and thus provided an additional tool for risk stratiﬁcation
after AMI, we do not yet know whether early recognition of
these patients as MetS will mitigate this excessive risk. We
also do not know if more aggressive lifestyle interventions
beyond those routinely prescribed to patients with AMI
provide additional beneﬁt in these high-risk patients. Future
studies are needed to determine whether identifying patients
as MetS during their AMI will improve outcomes.
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708Conclusions
In this multicenter registry of patients with AMI, we found
that MetS was exceedingly common, could be diagnosed with
reasonable accuracy during hospitalization, and was associ-
ated with increased risk of death or rehospitalization over the
12 months following AMI. Patients who were classiﬁed as
MetS during the acute event but did not qualify at follow-up
still represented a high-risk group, underscoring the impor-
tance of identifying these patients during their initial hospi-
talization. Further work that seeks to identify patients with
MetS prospectively during AMI and institute more aggres-
sive lifestyle changes may help reduce the excess risk for poor
long-term outcomes in this population.
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APPENDIX
For an expanded methods section and supplemental ﬁgures and a table,
please see the online version of this article.
